Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 485 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR How erectile dysfunction drugs could be the key to overcoming treatment... June 21, 2022 EMA Recommends Granting a Marketing Authorisation for Tarlatamab April 17, 2026 Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma October 20, 2023 Studying Genes and Proteins Together Sheds New Light on Colon Cancer May 28, 2019 Load more HOT NEWS Autumn and Letting Go Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... Drinking Alcohol, Often Heavily, Common among People with Cancer and Long-Term... Opinion: ‘We’re making headway, but we can’t be complacent’
